UseCases_ArguminSci_Discourse  

PubMed:10945643 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-107 DRI_Background denotes Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.
T2 108-212 DRI_Background denotes Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS).
T3 213-349 DRI_Background denotes However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment.
T4 350-568 DRI_Background denotes Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and proliferation in human DCIS xenografts using an in vivo model.
T5 569-809 DRI_Approach denotes Women (n = 23) with mammographic microcalcification suggestive of DCIS were identified at the time of surgery (day 0), a sample of representative tissue was obtained, divided into multiple 2x2x1-mm xenografts, and implanted s.c. into female
T6 810-822 Token_Label.OUTSIDE denotes BALB/c nu/nu
T7 823-853 DRI_Approach denotes mice (eight xenografts/mouse).
T8 854-921 DRI_Background denotes Day 0 grafts underwent immunohistochemical assessment of ER status.
T9 922-1085 DRI_Unspecified denotes Fourteen days after implantation, four xenografts were retrieved and mice were randomly divided into one of three treatment groups: (a) insertion of a slow release
T10 1086-1107 Token_Label.OUTSIDE denotes 2-mg 17beta-estradiol
T11 1108-1243 DRI_Unspecified denotes pellet; (b) weekly 5-mg injections of the pure AE Faslodex (Zeneca Pharmaceuticals); and (c) injections of a control vehicle oil alone.
T12 1244-1333 DRI_Background denotes After 2 weeks of treatment, the remaining four xenografts were retrieved from each mouse.
T13 1334-1554 DRI_Background denotes Retrieved xenografts containing DCIS were assessed for morphological evidence of apoptotic cell death [apoptotic index (AI)] and cell proliferation (by immunohistochemical detection of the Ki67 proliferation antigen LI).
T14 1555-1732 DRI_Outcome denotes Both AI and LI were higher in the day 0 specimens of 16 ER- DCIS lesions compared with 7 ER+ DCIS lesions (mean values, 1.47% versus 0.32% and 20.6% versus 3.1%; both P<0.0001).
T15 1733-2055 DRI_Unspecified denotes AI and LI values within ER- DCIS did not differ between xenografts exposed to 17beta-estradiol or AE treatment compared with the controls or pretreatment values (mean AI and LI in estradiol-treated, antiestrogen-treated, and control groups 1.04% versus 0.98% versus 1.29% and 17.2% versus 20.5% versus 17.7% respectively).
T16 2056-2248 DRI_Background denotes In contrast, treatment of mice bearing ER+ DCIS xenografts with 17beta-estradiol raised both the AI (1.03% versus 0.40%, P = 0.03) and LI (11.0% versus 5.1%, P = 0.007) compared with controls.
T17 2249-2404 DRI_Background denotes AE therapy of ER+ DCIS xenografts did not affect proliferation but resulted in higher apoptosis than in controls (0.9% versus 0.4% respectively, P = 0.04).
T18 2405-2485 DRI_Outcome denotes AE therapy should be reserved for patients with estrogen receptor positive DCIS.